The Purdue Foundry Investment Fund reinvested in a $30m round for Symic that will support a phase 3 trial for a compound intended to improve vein graft surgery.

Symic Bio, a biopharmaceutical spinout of Purdue University, has completed a $30m series B round backed by all its existing investors, including Purdue Foundry Investment Fund, a vehicle backed by Purdue University focused on the institution’s spinouts.

Danish state-backed research fund Den Danske Forskningsfond as well as Lilly Ventures and Mitsui Global Investment, the corporate venturing units of pharmaceutical company Eli Lilly and diversified conglomerate Mitsui, also participated, as did Ally Bridge Group, InCube Ventures, Mission Bay Capital, QB3 Partners…